Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2371 to 2385 of 7712 results

  1. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development [GID-TA11626] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Deucravacitinib for treating active psoriatic arthritis TS ID 11981

    Awaiting development [GID-TA11510] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]

    In development [GID-TA11042] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development [GID-TA11405] Expected publication date: 18 September 2025

    Technology appraisal guidance
    In development

  5. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

      Status ...

    Medical technologies guidance
    Topic selection

  6. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Targeted muscle reinnervation for managing limb amputation pain

    In development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    In development

  8. Laparoscopic lumbar sympathectomy for foot hyperhidrosis

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  9. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]

    In development [GID-TA11452] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  10. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years TSID 12054

    Awaiting development [GID-TA11636] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071

    Awaiting development [GID-TA11634] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046

    Awaiting development [GID-TA11632] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development [GID-TA11501] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    In development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    In development